Stock Watch: The Pandemic Brings Christmas Presents
Analyst Upgrades And Deferrals of Drug Pricing Legislation May Appear As Year-End Gifts
While the Omicron variant does not bode well for 2022, vaccine boosters and oral antivirals are the products from the pharmaceutical sector that should keep on giving. Even if partisan analysts choose to forget them.
You may also be interested in...
While Merck & Co’s Lagevrio’s results declined after an interim readout, Pfizer’s oral COVID-19 candidate Paxlovid has maintained its strong performance in protecting high-risk patients from hospitalization or death.
The Build Back Better Act has been updated to exempt generics experiencing or at risk of shortage from its planned inflation rebates, as well as biosimilars. But the US Association for Accessible Medicines has called for further changes to the proposed bill to protect off-patent drugs.
The evolution of new drugs to treat diabetes has enabled some diabetes franchises to shrug off biosimilar competition to insulins. But is some of the growth of therapies for diabetes and obesity a result of the pandemic?